Ultrafiltration Versus IV Diuretics in Worsening Heart Failure
Terminated · Not applicable · NCT05318105
Conditions: Heart Failure (for Example, Fluid Overload), Heart Failure, Fluid Overload
At a glance
- Research payments reported, 2025
- $285,292
- U.S. investigators named
- 16
- Sites paid
- 13
- Planned or actual enrollment
- 167
About the trial
- Sponsor
- Nuwellis, Inc.
- Tested
- Aquadex Smartflow® System (device), IV Loop Diuretics (drug)
- Dates
- Started 2022-06-28; completion 2026-04-07
- Results posted
- Not yet
The REVERSE-HF study is a randomized controlled trial to evaluate clinical outcomes of adjustable ultrafiltration with the Aquadex System as compared to adjustable IV loop diuretics in patients with worsening heart failure (HF) and fluid overload.
From ClinicalTrials.gov, last updated 2026-06-25. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Nuwellis, Inc. reported $285,292 in research payments for this study in 2025 (63 payments).
Products named: Aquadex Smartflow Console
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Radha S. Gopalan, MD Heart Failure & Transplant Cardiology · Phoenix, AZ
- Brian E. Jaski, M.D. Heart Failure & Transplant Cardiology · San Diego, CA
- Andrew J. Yoon, M.D. Heart Failure & Transplant Cardiology · Long Beach, CA
- Hakan R. Toka, MD, PHD Nephrology (Kidney) · Bradenton, FL
- Jennifer A. Cowger, MD Heart Failure & Transplant Cardiology · Detroit, MI
- Donald C. Haas, MD Heart Failure & Transplant Cardiology · Lawrenceville, NJ
- Ashish A. Correa, MD Cardiology · New York, NY
- Umesh K. Gidwani, MD, MS Cardiology · New York, NY
- Hassan A. Suleiman, MD Internal Medicine · New York, NY
- Sirish Vullaganti, M.D. Heart Failure & Transplant Cardiology · Manhasset, NY
- Sitaramesh Emani, M.D. Heart Failure & Transplant Cardiology · Cincinnati, OH
- Andrew R. Kolodziej, M.D. Heart Failure & Transplant Cardiology · Cincinnati, OH
- Vaiibhav N. Patel, MD Heart Failure & Transplant Cardiology · Columbus, OH
- Shree R. Mulay, MD Nephrology (Kidney) · Dyersburg, TN
- Jaime A. Hernandez Montfort, M.D. Cardiology · Round Rock, TX
- Amin A. Yehya, MD Heart Failure & Transplant Cardiology · Norfolk, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Jackson-Madison County General Hospital, TN $64,744
- Icahn School of Medicine at Mt Sinai $63,012
- Baylor Research Institute $36,150
- Wcg Irb LLC. $27,263
- University of Kentucky Research Foundation $22,710
- The Ohio State University $18,615
- Thomas Jefferson University $13,876
- Sentara Norfolk General Hospital $12,315
- Biomedical Research Alliance of New York, LLC $11,782
- Sterling Independent Services Inc $6,075
- Nova Clinical Research Centers LLC $6,000
- The Carl & Elyth Linder Center for Research and Education $1,999
- San Diego Cardiac Center Medial Group Inc $750
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.